2-(4-Chloro-2-methoxyphenyl)ethan-1-ol | 193290-24-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-Chloro-2-methoxyphenyl)ethan-1-ol
• 英文别名: 2-(4-chloro-2-methoxyphenyl)ethanol
• CAS: 193290-24-3
• 化学式: C₉H₁₁ClO₂
• 分子量: 186.63
• InChiKey: WZLFAOGIWTWHHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SUBSTITUTED AMINOTETRALINES
  申请人：Firooznia Fariborz

  公开号：US20100041713A1

  公开（公告）日：2010-02-18

  The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R 1 -R 4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

  这项发明涉及式I的化合物： 及其药用可接受的盐和酯，其中R1-R4在详细说明和权利要求中有定义。此外，本发明涉及制造和使用式I的化合物的方法，以及含有这种化合物的药物组合物。式I的化合物是CRTH2受体的拮抗剂，可能在治疗与该受体相关的疾病和紊乱方面有用，如哮喘。
• [EN] HETEROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE HETEROCYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2004076424A1

  公开（公告）日：2004-09-10

  Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式(I)的化合物对于抑制蛋白激酶是有用的。还公开了制造这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。
• NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION
  申请人：LABORATORIOS MENARINI S.A.

  公开号：EP0874826A1

  公开（公告）日：1998-11-04
• HETEROCYCLIC KINASE INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP1606268A1

  公开（公告）日：2005-12-21
• HISTONE DEMETHYLASE INHIBITORS
  申请人：Gwaltney Stephen

  公开号：US20190055212A1

  公开（公告）日：2019-02-21

  This disclosure relates to compounds that inhibit histone demethylase activity. In particular, the disclosure relates to compounds that inhibit histone lysine demethylase KDM5B, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions disclosed herein.